---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-055164"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2026-05-12T21:00:09+00:00"
generated_at: "2026-05-12T21:04:01.373246+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Relmada reports Q1 2026 net loss of $19.1M; NDV-01 Phase 2 shows 95% CR rate; cash $234M through 2029

## Summary
- NDV-01 12-month Phase 2 in high-risk NMIBC: 95% CR at any time, 76% durable CR; BCG-unresponsive: 94% CR, 80% durable.
- Cash balance $234.0M as of March 31, 2026, expected to fund operations through 2029 after $160M PIPE in March.
- Net loss $19.1M ($0.22/share) vs $17.6M ($0.58) Q1 2025; R&D expense $8.1M; G&A $11.4M.
- Phase 3 RESCUE registrational program on track for mid-2026; provisional patent filed April 2026 with term to 2047.
- Upcoming milestones: IND filing mid-2026, initial Phase 3 data by YE 2026, Sepranolone Phase 2 in Prader-Willi mid-2026.

## SEC filing metadata
- accession: 0001213900-26-055164
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2026-05-12T21:00:09+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/0001213900-26-055164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/ea0290414-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-055164
- JSON: https://secwatch.observer/filing/0001213900-26-055164.json
- Plain text: https://secwatch.observer/filing/0001213900-26-055164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.